Tranylcypromine

ترانیل‌سیپرومین

⚠ Unverified

🧠 Nervous SystemMAO inhibitor (non-selective)

Market / country: 🇺🇸 USA

Parnate (US)

🧮 Dose calculator

Major depressive disorder · Regimen source: FDA Tranylcypromine · 2.1

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

  • ⛔ Other MAOIs, SSRIs, SNRIs, tricyclics, sympathomimetics and many other drugs (label Table 1); pheochromocytoma or catecholamine-releasing paraganglioma. FDA Tranylcypromine · 4

Warnings

  • • Boxed warning: suicidality in children and young adults; hypertensive crisis with significant tyramine intake (aged cheese, cured meats…). FDA Tranylcypromine · Boxed Warning
  • • Serotonin syndrome; mania; hypotension; hepatotoxicity; seizures; hypoglycaemia in diabetics. FDA Tranylcypromine · 5

Formulations

👥 Special populations

  • 🤰 PregnancyUse with caution

    Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Tranylcypromine · 8.1

    “Risk Summary There are limited published reports of placental infarction and congenital anomalies in association with use of tranylcypromine sulfate tablets during pregnancy; however, these reports may not adequately inform the presence or absence of drug-associated risk with the use of tranylcypromine sulfate tablets …”
  • 🤱 BreastfeedingUse with caution

    Label: use with caution while breastfeeding; see the label text. FDA Tranylcypromine · 8.2

    “Risk Summary Tranylcypromine is present in human milk.”
  • 👶 ChildrenDangerous / avoid

    Boxed warning in the label about children. FDA Tranylcypromine · Boxed Warning

    “Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies.”
  • 👴 Older adultsUse with caution

    Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Tranylcypromine · 8.5

    “In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”
  • ⚥ Females & males of reproductive potentialNo data

    The source for this drug has no section for this group.

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Information on this site is compiled from online websites and references. Doz accepts no responsibility for self-medication without approval from a physician and a reliable reference, or for any consequences of using this information.

Inspired by the Saphira project; part of the content is taken from it.

For suggestions, corrections, adding drugs or anything else, you can contact me on Telegram: @cenaav